Deciphera rises on GIST response data, proposes follow-on

Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) added $12.40 (48%) to $38.31 on Monday after reporting updated data from heavily pretreated patients with gastrointestinal stromal tumors who received the company's DCC-2618 in a Phase I trial. The data were

Read the full 361 word article

User Sign In